Which has better earnings and valuation, TMDX or INMD?

TransMedics Group has higher revenue and earnings than InMode. InMode is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $605.49M 4.93 $190.29M $3.89 22.22 InMode $370.49M 2.23 $93.83M $1.23 11.67

Does the media refer more to TMDX or INMD?

In the previous week, TransMedics Group had 9 more articles in the media than InMode. MarketBeat recorded 12 mentions for TransMedics Group and 3 mentions for InMode. InMode's average media sentiment score of 0.65 beat TransMedics Group's score of 0.62 indicating that InMode is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InMode 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, INMD or ATRC?

InMode has higher earnings, but lower revenue than AtriCure. InMode is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $370.49M 2.23 $93.83M $1.23 11.67 AtriCure $534.53M 5.53 -$11.45M $0.21 276.67

Is INMD or ATRC more profitable?

InMode has a net margin of 20.69% compared to AtriCure's net margin of 1.85%. InMode's return on equity of 11.99% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets InMode 20.69% 11.99% 10.60% AtriCure 1.85% 2.34% 1.77%

Does the media prefer INMD or ATRC?

In the previous week, AtriCure had 6 more articles in the media than InMode. MarketBeat recorded 9 mentions for AtriCure and 3 mentions for InMode. AtriCure's average media sentiment score of 0.78 beat InMode's score of 0.65 indicating that AtriCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AtriCure 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, INMD or AXGN?

InMode has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $370.49M 2.23 $93.83M $1.23 11.67 AxoGen $225.21M 10.56 -$15.70M -$0.68 N/A

Is INMD or AXGN more profitable?

InMode has a net margin of 20.69% compared to AxoGen's net margin of -13.36%. InMode's return on equity of 11.99% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets InMode 20.69% 11.99% 10.60% AxoGen -13.36% -8.90% -6.47%

Does the media refer more to INMD or AXGN?

In the previous week, InMode had 1 more articles in the media than AxoGen. MarketBeat recorded 3 mentions for InMode and 2 mentions for AxoGen. AxoGen's average media sentiment score of 0.67 beat InMode's score of 0.65 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ESTA or INMD?

InMode has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Establishment Labs $211.08M 9.78 -$51.06M -$1.31 N/A InMode $370.49M 2.23 $93.83M $1.23 11.67

Is ESTA or INMD more profitable?

InMode has a net margin of 20.69% compared to Establishment Labs' net margin of -15.82%. InMode's return on equity of 11.99% beat Establishment Labs' return on equity. Company Net Margins Return on Equity Return on Assets Establishment Labs -15.82% -196.69% -10.73% InMode 20.69% 11.99% 10.60%

Does the media favor ESTA or INMD?

In the previous week, InMode had 2 more articles in the media than Establishment Labs. MarketBeat recorded 3 mentions for InMode and 1 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.81 beat InMode's score of 0.65 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive InMode 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, INSP or INMD?

Inspire Medical Systems has higher revenue and earnings than InMode. InMode is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inspire Medical Systems $911.98M 2.44 $145.42M $4.62 16.63 InMode $370.49M 2.23 $93.83M $1.23 11.67

Does the media favor INSP or INMD?

In the previous week, Inspire Medical Systems had 4 more articles in the media than InMode. MarketBeat recorded 7 mentions for Inspire Medical Systems and 3 mentions for InMode. Inspire Medical Systems' average media sentiment score of 0.92 beat InMode's score of 0.65 indicating that Inspire Medical Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inspire Medical Systems 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InMode 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

InMode (INMD) Competitors

$14.35 -0.19 (-1.31%)

Closing price 04:00 PM Eastern

Extended Trading

$14.52 +0.17 (+1.16%)

As of 07:50 PM Eastern

Compare

INMD vs. TMDX, ATRC, AXGN, ESTA, and INSP

Should you buy InMode stock or one of its competitors? InMode's main competitors and comparable companies include TransMedics Group (TMDX), AtriCure (ATRC), AxoGen (AXGN), Establishment Labs (ESTA), and Inspire Medical Systems (INSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does InMode compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and InMode (NASDAQ:INMD) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 68.0% of InMode shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Comparatively, 6.9% of InMode shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

TransMedics Group presently has a consensus price target of $121.10, suggesting a potential upside of 40.13%. InMode has a consensus price target of $16.00, suggesting a potential upside of 11.50%. Given TransMedics Group's stronger consensus rating and higher possible upside, equities analysts plainly believe TransMedics Group is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

TransMedics Group has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, InMode has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market.

TransMedics Group has a net margin of 22.69% compared to InMode's net margin of 20.69%. TransMedics Group's return on equity of 15.88% beat InMode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
InMode	20.69%	11.99%	10.60%

In the previous week, TransMedics Group had 9 more articles in the media than InMode. MarketBeat recorded 12 mentions for TransMedics Group and 3 mentions for InMode. InMode's average media sentiment score of 0.65 beat TransMedics Group's score of 0.62 indicating that InMode is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InMode	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has higher revenue and earnings than InMode. InMode is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.93	$190.29M	$3.89	22.22
InMode	$370.49M	2.23	$93.83M	$1.23	11.67

Summary

TransMedics Group beats InMode on 13 of the 16 factors compared between the two stocks.

How does InMode compare to AtriCure?

InMode (NASDAQ:INMD) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

InMode has a net margin of 20.69% compared to AtriCure's net margin of 1.85%. InMode's return on equity of 11.99% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	20.69%	11.99%	10.60%
AtriCure	1.85%	2.34%	1.77%

68.0% of InMode shares are owned by institutional investors. Comparatively, 99.1% of AtriCure shares are owned by institutional investors. 6.9% of InMode shares are owned by company insiders. Comparatively, 4.0% of AtriCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

InMode has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, AtriCure has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

InMode has higher earnings, but lower revenue than AtriCure. InMode is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.23	$93.83M	$1.23	11.67
AtriCure	$534.53M	5.53	-$11.45M	$0.21	276.67

In the previous week, AtriCure had 6 more articles in the media than InMode. MarketBeat recorded 9 mentions for AtriCure and 3 mentions for InMode. AtriCure's average media sentiment score of 0.78 beat InMode's score of 0.65 indicating that AtriCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AtriCure	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InMode presently has a consensus target price of $16.00, indicating a potential upside of 11.50%. AtriCure has a consensus target price of $53.30, indicating a potential downside of 8.26%. Given InMode's higher possible upside, research analysts plainly believe InMode is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

AtriCure beats InMode on 9 of the 17 factors compared between the two stocks.

How does InMode compare to AxoGen?

InMode (NASDAQ:INMD) and AxoGen (NASDAQ:AXGN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

InMode has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.23	$93.83M	$1.23	11.67
AxoGen	$225.21M	10.56	-$15.70M	-$0.68	N/A

InMode has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market. Comparatively, AxoGen has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

68.0% of InMode shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 6.9% of InMode shares are held by company insiders. Comparatively, 2.4% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

InMode has a net margin of 20.69% compared to AxoGen's net margin of -13.36%. InMode's return on equity of 11.99% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	20.69%	11.99%	10.60%
AxoGen	-13.36%	-8.90%	-6.47%

InMode currently has a consensus price target of $16.00, indicating a potential upside of 11.50%. AxoGen has a consensus price target of $51.56, indicating a potential upside of 16.56%. Given AxoGen's stronger consensus rating and higher possible upside, analysts plainly believe AxoGen is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, InMode had 1 more articles in the media than AxoGen. MarketBeat recorded 3 mentions for InMode and 2 mentions for AxoGen. AxoGen's average media sentiment score of 0.67 beat InMode's score of 0.65 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

InMode beats AxoGen on 10 of the 16 factors compared between the two stocks.

How does InMode compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and InMode (NASDAQ:INMD) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

InMode has a net margin of 20.69% compared to Establishment Labs' net margin of -15.82%. InMode's return on equity of 11.99% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-15.82%	-196.69%	-10.73%
InMode	20.69%	11.99%	10.60%

In the previous week, InMode had 2 more articles in the media than Establishment Labs. MarketBeat recorded 3 mentions for InMode and 1 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.81 beat InMode's score of 0.65 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
InMode	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InMode has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	9.78	-$51.06M	-$1.31	N/A
InMode	$370.49M	2.23	$93.83M	$1.23	11.67

Establishment Labs presently has a consensus price target of $100.25, suggesting a potential upside of 44.66%. InMode has a consensus price target of $16.00, suggesting a potential upside of 11.50%. Given Establishment Labs' stronger consensus rating and higher probable upside, equities research analysts clearly believe Establishment Labs is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Establishment Labs has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, InMode has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market.

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 10.0% of Establishment Labs shares are held by company insiders. Comparatively, 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

InMode beats Establishment Labs on 9 of the 16 factors compared between the two stocks.

How does InMode compare to Inspire Medical Systems?

Inspire Medical Systems (NYSE:INSP) and InMode (NASDAQ:INMD) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

In the previous week, Inspire Medical Systems had 4 more articles in the media than InMode. MarketBeat recorded 7 mentions for Inspire Medical Systems and 3 mentions for InMode. Inspire Medical Systems' average media sentiment score of 0.92 beat InMode's score of 0.65 indicating that Inspire Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inspire Medical Systems	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InMode	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inspire Medical Systems has higher revenue and earnings than InMode. InMode is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspire Medical Systems	$911.98M	2.44	$145.42M	$4.62	16.63
InMode	$370.49M	2.23	$93.83M	$1.23	11.67

InMode has a net margin of 20.69% compared to Inspire Medical Systems' net margin of 15.03%. InMode's return on equity of 11.99% beat Inspire Medical Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspire Medical Systems	15.03%	8.64%	7.45%
InMode	20.69%	11.99%	10.60%

Inspire Medical Systems has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, InMode has a beta of 1.86, suggesting that its stock price is 86% more volatile than the broader market.

Inspire Medical Systems currently has a consensus price target of $66.50, suggesting a potential downside of 13.47%. InMode has a consensus price target of $16.00, suggesting a potential upside of 11.50%. Given InMode's higher possible upside, analysts clearly believe InMode is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspire Medical Systems	3 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.21
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

94.9% of Inspire Medical Systems shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 2.2% of Inspire Medical Systems shares are held by company insiders. Comparatively, 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Inspire Medical Systems beats InMode on 11 of the 17 factors compared between the two stocks.

Get InMode News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INMD vs. The Competition

Export

Metric	InMode	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$835.77M	$5.54B	$7.26B	$13.71B
Dividend Yield	N/A	1.79%	2.57%	12.94%
P/E Ratio	11.67	25.10	273.80	25.39
Price / Sales	2.23	72.26	644.56	89.19
Price / Cash	9.75	32.72	77.42	51.66
Price / Book	1.33	5.74	10.45	6.33
Net Income	$93.83M	$151.55M	$3.48B	$358.24M
7 Day Performance	-3.69%	0.70%	0.88%	1.20%
1 Month Performance	-4.27%	-3.10%	0.03%	-2.04%
1 Year Performance	-5.41%	13.18%	18.28%	5.41%

InMode Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INMD InMode	1.7787 of 5 stars	$14.35 -1.3%	$16.00 +11.5%	-2.6%	$835.77M	$370.49M	11.67	660
TMDX TransMedics Group	4.2306 of 5 stars	$85.86 +4.5%	$124.18 +44.6%	-27.7%	$2.84B	$668.47M	22.07	898
ATRC AtriCure	2.2683 of 5 stars	$55.79 +2.3%	$52.00 -6.8%	+68.9%	$2.77B	$534.53M	265.68	1,350	Analyst Forecast
AXGN AxoGen	2.2447 of 5 stars	$43.78 +3.8%	$51.56 +17.8%	+169.2%	$2.27B	$225.21M	N/A	622
ESTA Establishment Labs	2.8782 of 5 stars	$71.92 +1.4%	$100.25 +39.4%	+77.9%	$2.11B	$245.82M	N/A	1,004

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INMD) was last updated on 9/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InMode (INMD) Competitors

INMD vs. TMDX, ATRC, AXGN, ESTA, and INSP

How does InMode compare to TransMedics Group?

Summary

How does InMode compare to AtriCure?

Summary

How does InMode compare to AxoGen?

Summary

How does InMode compare to Establishment Labs?

Summary

How does InMode compare to Inspire Medical Systems?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMD vs. The Competition

InMode Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InMode (INMD) Competitors

INMD vs. TMDX, ATRC, AXGN, ESTA, and INSP

How does InMode compare to TransMedics Group?

Do insiders & institutionals hold more shares of TMDX or INMD?

Do analysts prefer TMDX or INMD?

Which has more risk & volatility, TMDX or INMD?

Is TMDX or INMD more profitable?

Does the media refer more to TMDX or INMD?

Which has better earnings and valuation, TMDX or INMD?

Summary

How does InMode compare to AtriCure?

Is INMD or ATRC more profitable?

Do insiders and institutionals have more ownership in INMD or ATRC?

Which has more volatility & risk, INMD or ATRC?

Which has better valuation and earnings, INMD or ATRC?

Does the media prefer INMD or ATRC?

Do analysts rate INMD or ATRC?

Summary

How does InMode compare to AxoGen?

Which has better valuation & earnings, INMD or AXGN?

Which has more risk & volatility, INMD or AXGN?

Do institutionals and insiders believe in INMD or AXGN?

Is INMD or AXGN more profitable?

Do analysts rate INMD or AXGN?

Does the media refer more to INMD or AXGN?

Summary

How does InMode compare to Establishment Labs?

Is ESTA or INMD more profitable?

Does the media favor ESTA or INMD?

Which has higher valuation and earnings, ESTA or INMD?

Do analysts rate ESTA or INMD?

Which has more volatility and risk, ESTA or INMD?

Do institutionals and insiders believe in ESTA or INMD?

Summary

How does InMode compare to Inspire Medical Systems?

Does the media favor INSP or INMD?

Which has stronger earnings and valuation, INSP or INMD?

Is INSP or INMD more profitable?

Which has more volatility & risk, INSP or INMD?

Do analysts prefer INSP or INMD?

Do insiders & institutionals hold more shares of INSP or INMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMD vs. The Competition

InMode Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools